1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
  4. > Xifaxan (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Xifaxan (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

  • December 2014
  • -
  • GlobalData
  • -
  • 59 pages

Summary

Table of Contents

Search Inside

Xifaxan (Irritable Bowel Syndrome) - Forecast and Market Analysis to 2023

Summary

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

Xifaxan (rifaximin) was developed by Alfa Wassermann, and is currently approved for the treatment of hepatic encephalopathy and traveler's diarrhea in the US and 5EU, except in France. In 1996, Salix Pharmaceuticals gained the exclusive rights to Xifaxan in the US, and is currently developing this product for the treatment of patients with IBS-D (Salix Pharmaceuticals, 2014).

Scope

- Overview of IBS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Xifaxan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Xifaxan for the top 7 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, and Japan.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for IBS.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Xifaxan performance.
- Obtain sales forecast for Xifaxan from 2013-2023 in top 7 countries (the US, France, Germany, Italy, Spain, the UK, and Japan).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Irritable Bowel Syndrome in 12 Major Markets Irritable Bowel Syndrome (IBS) is a functional bowel disorder which incorporates a group ...

Gastroesophageal Reflux Disease (GERD)  - Market Insights, Epidemiology and Market Forecast-2023

Gastroesophageal Reflux Disease (GERD)  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Gastroesophageal Reflux Disease (GERD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Gastroesophageal ...

Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023

Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Irritable Bowel Syndrome - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


Download Unlimited Documents from Trusted Public Sources

Gastrointestinal Drug Industry in Canada

  • March 2017
    92 pages
  • Gastrointestina...  

    Health Care Pro...  

    Ambulatory Care  

  • Canada  

    North America  

View report >

Gastrointestinal Drug Industry in Canada

  • March 2017
    92 pages
  • Gastrointestina...  

    Health Care Pro...  

    Ambulatory Care  

  • Canada  

    North America  

View report >

Gastrointestinal Drug Industry in the US - Forecast

  • January 2017
    4 pages
  • Gastrointestina...  

    Digestive Syste...  

    Hormone  

  • United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.